1071 related articles for article (PubMed ID: 14698315)
1. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
3. Bax protein expression in colorectal cancer: association with p53, bcl-2 and patterns of relapse.
Giatromanolaki A; Sivridis E; Stathopoulos GP; Fountzilas G; Kalofonos HP; Tsamandas A; Vrettou E; Scopa C; Polychronidis A; Simopoulos K; Koukourakis MI
Anticancer Res; 2001; 21(1A):253-9. PubMed ID: 11299743
[TBL] [Abstract][Full Text] [Related]
4. Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients?
Kymionis GD; Dimitrakakis CE; Konstadoulakis MM; Arzimanoglou I; Leandros E; Chalkiadakis G; Keramopoulos A; Michalas S
J Surg Res; 2001 Aug; 99(2):161-8. PubMed ID: 11469882
[TBL] [Abstract][Full Text] [Related]
5. Image cytometric bcl-2:bax and bcl-2:bcl-x ratios in invasive breast carcinoma: correlation with prognosis.
Schiller AB; Clark WS; Cotsonis G; Lawson D; DeRose PB; Cohen C
Cytometry; 2002 Aug; 50(4):203-9. PubMed ID: 12210599
[TBL] [Abstract][Full Text] [Related]
6. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
7. Immunofluorometric study of Bcl-2 and Bax expression in clinical fresh tumor samples from breast cancer patients.
Martínez-Arribas F; Núñez-Villar MJ; Lucas AR; Sánchez J; Tejerina A; Schneider J
Anticancer Res; 2003; 23(1B):565-8. PubMed ID: 12680147
[TBL] [Abstract][Full Text] [Related]
8. Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers.
Krajewski S; Thor AD; Edgerton SM; Moore DH; Krajewska M; Reed JC
Clin Cancer Res; 1997 Feb; 3(2):199-208. PubMed ID: 9815673
[TBL] [Abstract][Full Text] [Related]
9. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.
el-Ahmady O; el-Salahy E; Mahmoud M; Wahab MA; Eissa S; Khalifa A
Anticancer Res; 2002; 22(4):2493-9. PubMed ID: 12174951
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of bcl-2, bax, and p53 expression in diffuse large B-cell lymphoma.
Sohn SK; Jung JT; Kim DH; Kim JG; Kwak EK; Park Ti; Shin DG; Sohn KR; Lee KB
Am J Hematol; 2003 Jun; 73(2):101-7. PubMed ID: 12749011
[TBL] [Abstract][Full Text] [Related]
11. Reciprocal expression of Bcl-2 and p53 in breast ductal carcinoma.
Lee WY; Jin YT; Tzeng CC
Anticancer Res; 1996; 16(5A):3007-12. PubMed ID: 8917421
[TBL] [Abstract][Full Text] [Related]
12. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases.
Wang-Rodriguez J; Cross K; Gallagher S; Djahanban M; Armstrong JM; Wiedner N; Shapiro DH
Mod Pathol; 2002 Aug; 15(8):853-61. PubMed ID: 12181271
[TBL] [Abstract][Full Text] [Related]
13. [Clinical characteristics and prognosis of breast cancer patients with vascular invasion].
Zhao WH; Xu BH; Zhang P; Li Q; Zhao LM; Sun Y
Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):137-40. PubMed ID: 17645853
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of p53/bcl-2 co-expression in patients with laryngeal squamous cell carcinoma.
Jäckel MC; Sellmann L; Dorudian MA; Youssef S; Füzesi L
Laryngoscope; 2000 Aug; 110(8):1339-45. PubMed ID: 10942137
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of apoptosis-regulating protein expression in anal squamous cell carcinoma.
Allal AS; Waelchli L; Bründler MA
Clin Cancer Res; 2003 Dec; 9(17):6489-96. PubMed ID: 14695153
[TBL] [Abstract][Full Text] [Related]
16. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
Bottini A; Berruti A; Bersiga A; Brizzi MP; Brunelli A; Gorzegno G; DiMarco B; Aguggini S; Bolsi G; Cirillo F; Filippini L; Betri E; Bertoli G; Alquati P; Dogliotti L
Clin Cancer Res; 2000 Jul; 6(7):2751-8. PubMed ID: 10914720
[TBL] [Abstract][Full Text] [Related]
17. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
Yu H; Levesque MA; Clark GM; Diamandis EP
Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
[TBL] [Abstract][Full Text] [Related]
18. Primary breast cancer phenotypes associated with propensity for central nervous system metastases.
Tham YL; Sexton K; Kramer R; Hilsenbeck S; Elledge R
Cancer; 2006 Aug; 107(4):696-704. PubMed ID: 16826579
[TBL] [Abstract][Full Text] [Related]
19. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
20. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
